2024-12-13 04:45:53
IEA monthly report: global oil inventories rebounded in November. OECD crude oil inventories fell by 30.9 million barrels in October. It was observed that global oil inventories fell by 39.3 million barrels in October.Japan's Shimane nuclear power plant operating company said that there was no abnormality in the reactor water level gauge of Unit 2, which was previously misjudged. On December 12, local time, China Electric Power Company of Japan conducted an investigation on the report that the reactor water level gauge of Unit 2 of Shimane nuclear power plant was once abnormal, and the results showed that there was no abnormality. The company said that the value displayed by the instrument was normal, but the operator misunderstood the data and misjudged it as abnormal. (CCTV News)Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.
Deputy Prime Minister of Ukraine: We are ready to discuss the deployment of foreign troops in our own territory. On December 12, local time, the reporter of the General Desk learned that Ukrainian Deputy Prime Minister Stefani Hina said that Ukraine is ready to discuss the deployment of foreign troops in its own territory. It is reported that French President Macron and Polish Prime Minister Tusk plan to exchange views on the deployment of about 40,000 peacekeepers in Uzbekistan on the 12th. (CCTV News)Jichuan Pharmaceutical Co., Ltd. and Dongke Pharmaceutical Co., Ltd., a wholly-owned subsidiary, have recently received the Drug Registration Certificate for Children Faropenem Sodium Granules and Cefezoxime Sodium for Injection approved and issued by National Medical Products Administration.People's Insurance Company of China: In the first November, the original insurance premium income of the three subsidiaries totaled 646.933 billion yuan. From January 1, 2024 to November 30, 2024, the original insurance premium income obtained through the subsidiaries of China People's Property Insurance Co., Ltd., China People's Life Insurance Co., Ltd. and China People's Health Insurance Co., Ltd. was 496.845 billion yuan, 102.591 billion yuan and 47.497 billion yuan respectively.
Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.Li Ka-shing's H-share shareholding in China Postal Savings Bank decreased from 5.07% to 4.96%.